Filing Flows › Krystal Biotech (KRYS) › Q1 2025
Krystal Biotech (KRYS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Krystal Biotech (KRYS) reported revenue of $88.2M for the first quarter 2025 (Q1 2025), +95% from a year earlier and -3% from the quarter before. Operating margin was 41.1%, net earnings $35.7M (40.5% of revenue).
Krystal Biotech, Q1 2025: revenue $88.2M (+95% year over year), operating margin 41.1%, net earnings $35.7M, operating cash flow $31.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $88.2M | -3% | +95% |
| Operating profit | $36.3M | -12% | — |
| Net earnings | $35.7M | -21% | 38× |
| Operating cash flow | $31.0M | -41% | +95% |
| Free cash flow | $24.8M | -52% | +69% |
What changed
Revenue was $88.2M in Q1 2025, up 95% year over year and down 3% from the previous quarter.
Operating profit was $36.3M, a 41.1% margin (up 55.9 points year over year). Total costs fell 0% while revenue rose 95%. The fastest-growing cost line was Research & development (+30%). Net earnings were $35.7M, up 3734% year over year. The effective tax rate was 18.0%.
Operating cash flow was $31.0M (up 95% year over year), 87% of net earnings. Non-cash charges added back $1.4M of depreciation and $13.5M of share-based compensation. Working capital and other items used $19.7M. Capital expenditures of $6.2M left free cash flow of $24.8M.
Questions
What was Krystal Biotech's revenue in the first quarter 2025?
Krystal Biotech (KRYS) reported revenue of $88.2M for the first quarter 2025 (Q1 2025), +95% from a year earlier and -3% from the quarter before.
Was Krystal Biotech profitable in the first quarter 2025?
Operating profit was $36.3M (41.1% of revenue) and net earnings $35.7M.
Source: Krystal Biotech 10-Q on SEC EDGAR.